BREAKTHROUGHS IN HEALTHCARE EQUITY SYMPOSIUM
What Are the Challenges of Delivering Healthcare to Underserved Patient Groups?
San Francisco, CA, USA
San Francisco, CA, USA
The Breakthroughs in Healthcare Equity Symposium is a leading collaborative symposium for patients, patient groups, clinicians, researchers, technologists, healthcare and life science executives, and diversity and inclusion advocates to discuss equity in healthcare. The symposium brings these groups together in a collaborative forum to create networks, discuss best practices, and exchange new ideas related to making healthcare more equitable, with a specific focus on understanding how to serve underserved patient groups, including racial and ethnic minorities, women, and the LGBT community. The symposium will also focus on in helping provider, pharma, and other organizations who serve patients with the latest ideas and insights on how these organizations can become more equitable in order to best understand the unique and diverse needs of the patients they serve. Attendees will learn the newest insights and ideas, discuss practical solutions, and meet industry and marketplace colleagues.
a leading educational symposium on patient-centered health outcomes and diversity in the treatment of diverse patient populations that include the LGBT community, women, racial and ethnic minorities, and individuals of low socioeconomic status
new knowledge and ideas on the crucial role technology plays in making healthcare more equitable and how technology firms are innovating healthcare delivery
best practices for recruiting, retaining, and promoting a diverse workforce, from entry-level to C-Suite and boardrooms
how diversity and inclusion drive innovation within organizations
cross-sectorial and multi-industry collaboration and innovation by connecting key partners in industry, patient groups, providers, and academia
and share ideas with many of the country’s leading life science and healthcare professionals who are passionate about healthcare equity
on building an organizational culture that attracts the best and brightest people, resulting in a equitable workforce where all ideas are valued
the obstacles to clinical trials, comparative effectiveness research, and healthcare access for underrepresented patient populations
Ricki Fairley is the Founder, President and Thought Leader of DOVE Marketing, a marketing agency with a mission to deliver iconic thinking, strategic problem solving and creative genius to clients seeking profitable business results. Fairley is a seasoned marketer with over 30 years of marketing experience including 20 years in brand management at Johnson & Johnson, Nabisco, Reckitt & Colman and The Coca-Cola Company, and over ten years in agency leadership encompassing strategic planning and consulting for numerous Fortune 500 companies. She is passionate about helping clients identify marketplace opportunities, establish insight-based objectives and strategies, and build results-driven campaigns with resonating creative. Ricki holds the Leadership Award from the Creative Thinking Association of America, and was named a Top 100 Marketer by Black Enterprise Magazine in February 2011. In November 2013, Ricki received the Association of National Advertisers Multicultural Excellence Award for the African American advertising for the Obama for America campaign. In February 2014, Ricki was inducted into The HistoryMakers. In March 2014, she received the Game Changer Award from Café Mocha and the Atlanta Tribune. In May 2014, DOVE Marketing received the US Trade & Commerce Institute Excellence in Marketing Award. Ricki was featured as Chapter 8 in “The 50 Billion Dollar Boss,” New York Times Best Seller List 2016 for Best Business books.
Ricki holds a BA from Dartmouth College and an MBA from Kellogg School of Management at Northwestern University. She is the President Emeritus of the Black Alumni of Dartmouth Association, and serves on the board of Kenny Leon’s True Colors Theatre Company. Ricki is Chair of the Board of Trustees and chairs the Marketing Committee for the Triple Negative Breast Cancer Foundation and works diligently to garner publicity for breast cancer awareness. As a Stage 3A Triple Negative Breast Cancer Survivor/Thriver, she speaks regularly to advocate for awareness of the disease. She is also a member of the 2011 Class of Leadership Atlanta.
Mr. Deary Duffie, MBA, leads Diversity & Inclusion, and Learning & Organization Development functions at Genentech a biotechnology affiliate of Roche Pharmaceuticals. His team contributes to successful business outcomes in the areas leadership and executive development, culture change, and employee engagement. His current projects include, “Nurturing and Evolving the Genentech Culture for Sustained Agility and Competitiveness”, and “Increasing Organizational Learning by Sharing Failures in Public Forums”.
Deary’s work of over 30 years as a Senior Human Resources executive at companies such as Charles Schwab Corporation, Levi Strauss and Company, and Hewlett-Packard allowed for international assignments in Brazil, Singapore, Belgium, and Italy. He enjoys work that brings together different cultures and perspectives to create innovative, inclusive solutions.
Deary is a member of the Masters of Science in Organization Development (MSOD) Advisory Board in the School of Management at the University of San Francisco. The Advisory Board makes recommendations regarding the ongoing improvement of the MSOD program and provides guidance to maintain a high caliber graduate program. The Advisory Board is an integral part of the MSOD program as it bridges the gap between student experience, program content and learning, campus administration, and the “real world”.
Deary received his BA degree in Liberal Studies at University of California, Riverside and his MBA degree from the Haas School of Business at University of California, Berkeley. He is certified as an integral coach at New Ventures West in San Francisco.
Dr. Billy Vaughn, PhD, is passionate about helping people value “the other” as an extension of themselves in order to increase a sense of belonging. As a cognitive cultural psychologist, he commits his professional life to unlocking the keys to promoting inclusion competence and creating inclusive organizations. He founded DTUI.com LLC in 1998 to promote the cultural diversity practitioner profession and provide consulting and training solutions. Billy recently created the freestanding corporate university, Diversity Executive Leadership Academy (DELA), to provide professional credentialing training. Professionals across sectors turn to DELA for professional training, cultural diversity practitioner certification, and continuing education. He has developed assessment tools, simulation games, and most of the DELA curriculum. His contributions to the field also include several books, a number of academic publications, and professional articles in magazines and blogs. His current book is High Impact Cultural Diversity & Inclusion Initiatives, which is scheduled for publication in May 2018.
GAR (Gender, Age, and Race) Diversity Consulting
Dr. Barbara B. Adams, PsyD, is the Founder of GAR (Gender, Age, and Race) Diversity Consulting, based in the San Francisco Bay Area. She consults with healthcare, educational services and technology clients globally. Dr. Adams is the author of the forthcoming book: Women, Minorities, and Other Extraordinary People: The New Path to Workforce Diversity (Greenleaf Book Group, Sept. 2018). She has been featured in The Sacramento Bee; SiliconValley.com; WallStreetSelect; Miami Herald; and SignOn San Diego.
Dr. Adams is a former director in the National Diversity & Inclusion Office at Kaiser Permanente (KP), ranked #1 in the 2016 DiversityInc Top 50 survey. She holds a Doctorate of Psychology degree in Organizational Development.
More information is available at www.drbarbadams.com.
Dr. Thomas Summerfelt, PhD, is the President, North America at Convergence CT. Prior to this role, Dr. Summerfelt is the Vice President of Research & Innovation at Advocate Health Care. Dr. Summerfelt earned his PhD from Vanderbilt University and focused his doctoral and post-doctoral training on Health Services Research. He has held faculty appointments at Vanderbilt, Michigan State, and University of Chicago. His scholarly work focuses on effectiveness research, program evaluation, and value-based analysis. At Advocate Health Care, he has used his university experiences to craft innovative approaches to research administration and support to investigators while focused on patient outcomes, compliance, efficiency, and effectiveness.
San Francisco Department of Public Health
Dr. Ayanna Bennett, MD, MPH, is the Director of Interdivisional Initiatives for the San Francisco Department of Public Health. She provides executive leadership for initiatives that combine the resources of the department, including research, education, community engagement, and health care delivery, to improve community health. Dr. Bennett is a practicing pediatrician who maintained a private pediatric practice in the East Bay for 12 years. During that time she also co-founded the 3rd St Youth Center & Clinic in San Francisco, a non-profit youth center co-located with a part-time youth-focused clinic. Dr. Bennett holds a BA in Human Biology from Stanford University and a Masters from the UC Berkeley School of Public Health. She attended UCSF for both her MD and pediatric residency.
Dr. Manoja Lecamwasam, PhD, MBA, MS, is the Executive Director of the Dignity Health Intellectual Property (IP) Office. Dr. Lecamwasam is also a member of the Strategic Innovation function and is responsible for the introduction of innovative life sciences and device products and services into Dignity Health service areas. She was Dignity Health’s business lead for the establishment of the Precision Medicine Alliance (PMA), a joint venture with Catholic Health Initiatives (CHI), which will provide genomic-based decision support tools to Dignity Health’s and CHI’s community oncologists at point of care. She is currently a governance board member of the PMA. Dr. Lecamwasam holds a PhD degree in molecular microbiology from Tufts University School of Medicine, a MBA from the University of Phoenix, a MSc degree in molecular biology from Northeastern University, and BA with honors in biology from Mills College in Oakland, CA.
Ms. Regina Greer-Smith, MPH, is a member of the Advisory Panel for Patient Engagement at the Patient Centered Outcomes Research Institute (PCORI). Regina is the President and Owner of Healthcare Research Associates, LLC. Regina’s work includes building and maintaining collaborations between communities and stakeholders that enable improved healthcare outcomes. Regina is a consultant /healthcare coordinator to agencies providing services to developmentally and intellectually disabled adults in Illinois and the use of mobile technology to enable collaboration between patients/caregivers and providers. She is the developer and principal investigator of The S.T.A.R. Initiative. The mission of The S.T.A.R. Initiative is to increase minority participation in patient-centered outcomes research and clinical trials. Regina holds a MPH degree from Benedictine University and is a Fellow with The American College of Healthcare Executives.
Bridge Clinical Research
Dr. Owen Garrick, MD, MBA, is President & COO of Bridge Clinical Research. Bridge Clinical is a global patient recruitment healthcare communications company. It is also the leading company focused on increasing the participation of minority investigators and patients in clinical trials. Dr. Garrick was formerly Director of Corporate Strategy and M&A at McKesson. Prior to McKesson, Dr. Garrick was Global Head of M&A Negotiations at Novartis. Previously he was at Goldman Sachs in New York. Dr. Garrick earned his MD from Yale, MBA from Wharton. He holds an AB from Princeton University. Dr. Garrick also serves on the boards of Sutter Health, the American Psychiatric Association Foundation and Samuel Merritt University. He was confirmed to the HHS Secretary’s Advisory Committee on Human Research Protections in 2012.
Dr. Dana Pizzuti, MD, is Senior Vice President of Regulatory Affairs and Clinical Quality Assurance at Rigel Pharmaceuticals. Dr. Pizzuti has tremendous experience across the broad range of regulatory, clinical, NDA and commercial-stage functions. Dr. Pizzuti is a physician Board Certified in Internal Medicine and has over 25 years of pharmaceutical industry experience, working for companies such as Hoffmann-La Roche, Abbott Laboratories, Bristol Myers Squibb, Johnson and Johnson, and Gilead, before joining Rigel Pharmaceuticals in August 2017. Dr. Pizzuti received her MD from New York University School of Medicine. She completed her postgraduate training in Internal Medicine at New York University/Bellevue Hospitals and subspecialty training in Infectious Diseases at Montefiore Hospital-Albert Einstein School of Medicine in the Bronx, New York.
Dr. Uri Lopatin, MD, is a co-founder and the Chief Medical officer and VP R&D for Assembly Biosciences, Inc. Prior to Assembly, he was a Senior Director for Clinical and Translational Research-Liver Disease at Gilead Sciences, a Translational Medical Leader at Roche, and an Associate Director at Schering Plough. He has designed and coordinated pre-clinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published extensively, especially on hepatitis B and immunology and is an author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and Dentistry-New Jersey Medical School, where he was the recipient of the Stanley S Bergen medal of excellence. He holds a BA in biology from Cornell University, where he graduated cum laude with distinction in all subjects.
Dr. Todd Strumwasser, MD, is the Senior Vice President, Operations at Dignity Health. He is responsible for the Bay Area Service Area and an assigned portfolio of healthcare assets which includes acute care, ambulatory outpatient services, philanthropy, physician alignment and employment business models, as well as other alternative healthcare delivery systems. Prior to joining Dignity Health, Dr. Todd Strumwasser served as the Chief Executive of two hospitals in Seattle’s Swedish Health Services system, Swedish First Hill and Swedish Cherry Hill. Dr. Strumwasser graduated from the University of California, Davis, and received his M.D. from the University of Southern California. He completed a residency in anesthesiology from the University of Washington Affiliated Hospitals, where he served as chief resident. He completed a certificate in executive development at the University of Washington, Keck School of Business.
Dr. Arturo Molina, MD, MS, is the Chief Medical Officer at Sutro Biopharma. Dr. Arturo Molina, an oncologist, has led scientific innovation and driven clinical programs forward for over twenty years. With his extensive experience interacting with the FDA and other global regulatory bodies, he has led the development of hematological and oncologic clinical candidates from phase I through phase III and through post-marking trials. He joins Sutro from his former role as VP of oncology and scientific innovation at Johnson & Johnson’s California Innovation Center where he was involved in the evaluation of novel biologics and small molecules, with a focus on immuno-oncology. While working for Johnson & Johnson, Dr. Molina oversaw the approval of Zytiga® in a multitude of countries for metastatic castration resistant prostate cancer indications. Previously, Dr. Molina served as chief medical officer and executive vice-president of Cougar Biotechnology where his leadership efforts advanced the company’s abiraterone program, Zytiga®, from phase I into several global phase III studies. He played a substantial role in the diligence efforts which led to the near $1B acquisition of Cougar by Johnson & Johnson. Dr. Molina has also held leadership positions at Biogen Idec where he led the hematology/oncology clinical development team and oversaw the post-approval label expansion of Rituxan® in front-line follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Dr. Molina was a faculty staff physician and adjunct professor in hematology/bone marrow transplantation and medical oncology/therapeutics research at the City of Hope Comprehensive Cancer Center. Dr. Molina received his M.D. and M.S. degrees from Stanford University School of Medicine in Stanford, CA. He is board certified in internal medicine and medical oncology and has an active California medical license. He additionally has earned distinction as a Fellow of the American College of Physicians.
Dr. Joshua Newman, MD, MSHS, is Chief Medical Officer at Salesforce. Dr. Newman has a 15-year history in Health IT, having designed, built, and managed web applications that have been used to digitalize medical residency administration, billing, and clinical care, to promote collaboration between physicians, and to ease the adoption of electronic medical records systems. In his current role at Salesforce, he leads the strategy and cross-functional efforts on the company’s health products, develops partner and customer presence on the Salesforce development platform, and enables health applications for non-profit organizations through the Salesforce Foundation. Prior to Salesforce, he worked as a practicing physician and Assistant Clinical Professor of Medicine at UCLA with a research focus on health information technology. Dr. Newman received his MD from the University of Illinois at Chicago, and completed his residency in Family Medicine at the Advocate Illinois Masonic/UIC program. He completed a Robert Wood Johnson Clinical Scholars Program, a postgraduate fellowship at UCLA, and received an MSHS degree in Health Services. He is a member of a number of professional organizations around medicine and technology.
The Kaleidoscope Group
Mr. Doug Harris is the Chief Executive Officer of The Kaleidoscope Group with almost 30 years of experience in the field of diversity & inclusion consulting. Prior to joining Bea Young Associates in 1993, Doug worked for several years as a consultant and trainer for Harbridge House, Inc. where he facilitated diversity & inclusion education sessions with senior executives of Fortune 500 organizations. Today, as the leader of The Kaleidoscope Group, Doug empowers organizations to achieve their diversity and inclusion goals. His knowledge and expertise guides organizations through the creation of customized strategies that address the specific diversity needs of the business. He recently developed and launched The Kaleidoscope Group Youth Practice to assist underserved youth in the Chicagoland and surrounding communities and is working with Tufts University to design and implement a student leadership development program.
Building 83-1B | 611 Gateway Blvd.
South San Francisco, CA 94080
Please contact us with any symposium questions.